OncoGU

GU Medical Oncologists and Researchers. Excellence in teaching, researching and patient-centered care. @EZucca @CarcanoMD @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

After #ESMO20 How would you consider for treating in 1L your aRCC patients? #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[Eduardo Zucca @EZucca]

Sobre carcinoma urotelial de bexiga mx.
Qual o tratamento de escolha de 1 linha para pac inelegíveis a cisplatina? Carbo ou Imuno?
Para se aprofundar no assunto, vale a pena escutar o podcast @Uromigos #81 onde discute-se dois estudos apresentados na @ASCO #GU21 👉

[Toni Choueiri, MD @DrChoueiri]

#ESMO20 by the numbers —less than 1 week ago!

[OncoGU @GuOnco]

PROfound: The first positive phase III PARPi trial in a molecularly-defined subset of mCRPC significantly improved OS (19.1mos HR .69) with olaparib vs Enz/Abi in Cohort A (BRCA 1/2 or ATM) despite crossover (67%). #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

IPATential150: Ipatasertib + Abi as 1L in PTEN-loss mCRPC improves the rPFS (HR .77), ORR (61%) and time to PSA progression. OS data remain imature. The safety profile was in line with known and potential risks. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

Study designs in the precision oncology era (Basket and Umbrella trials). Specially for our residents/fellows. #oncogu #clinicalresearch @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

With an elegant study design (umbrella trial), BIONIKK is the 1st randomized clinical trial that provides evidence to guide aRCC 1L therapy (TKI, Nivo alone or Nivo-Ipi), based on molecular group assessment. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[Daniel Preto, MD, PhD @DD_Preto]

Oncology is a matter of tails... #tellingtails #survivalcurves #ESMO20 #oncogu

[OncoGU @GuOnco]

Great review about aRCC doublets 1L choices... #ESMO20 #oncogu #geniturinarycancers @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

CheckMate 9ER: Nivo+Cabo is a novel 1L option for aRCC regardless IMDC risk group or tumor PD-L1 expression. With a consistent PFS (HZ .51), OS (HZ .60) and ORR (29%) benefits over Sunitinib. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

COSMIC-021: Cabo+Atezo is a promising and safety combination for previously untreated aRCC, with a 58% ORR and 15.1 mPFS for 60mg QD Cabo dose group. Baseline PD-L1+ and high CD8 seems to have better response rate. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

There's still NO predictive biomarker, as assessed PD-L1 expression, high TMB and mutation signatures (either alone or in combination), that optimally predict OS benefit from avelumab 1L maintenance (JAVELIN Bladder 100 trial). #ESMO20 @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

TROPHY-U-01 trial: sacituzumab govitecan demonstrated an interesting efficacy (27% ORR; 5.9 mos mDOR; 5.4 mos mPFS) with manageable toxicity in cohort 1 (mUC pts after platinum and IO progression). Anxious about TROPiCS-04 trial. #ESMO20 @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

Great review about 1L mUC state of art in Sep-20. KN-361 and DANUBE trials dit not change the current clinical pratice. PD-L1 is not a useful biomarker for entire platinum-elegible pts and IO has still unclear benefit in this pop #ESMO20 @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

The DANUBE trial did not meet the co-primary endpoints of OS. However, there is a trend towards better OS with D vs chemo in the high PD-L1 population and with D+T vs chemo in ITT. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

PFS and OS benefit upon addition of Pembro to Chemo vs Chemo did not reach statistical significance in KN-361 trial. Avelumab as maintatenance therapy is still the SOC for pts who do not progress 1L platinum-based chemo. #ESMO20 #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

#ESMO20 #geniturinarycancers #oncogu #highlights @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[Tom Powles @tompowles1]

ESMO20 bladder cancer highlights 1) front line pembro +/- chemo vs chemo 2) tremi+durva vs durva vs chemo. We know both trials are -ve. What went wrong? 3) QOL data for atezo&chemo. 4) biomarkers, subset analysis and QOL data for maintenance avelumab. Will good results continue?

[OncoGU @GuOnco]

Anxious about #ESMO20 GU oral presentations: KEYNOTE-361, DANUBE, COSMIC-021, BIONIKK, CheckMate 9ER, IPATential150 trials and PROfound final OS. Soon this week. #geniturinarycancers #oncogu @CarcanoMD @EZucca @JoaoNeif @DD_Preto

[OncoGU @GuOnco]

Coming soon this week... #esmo #ESMO20 #geniturinarycancers #medicaloncology @CarcanoMD @EZucca @JoaoNeif @DD_Preto